Bone morphogenetic protein-associated complications in pediatric spinal fusion in the early postoperative period: An analysis of 4658 patients and review of the literature

Journal of Neurosurgery: Pediatrics

Volumn 14, Issue 6, 2014, Pages 635-643

  Rocque, Brandon G ^a   Kelly, Mick P ^b   Miller, Joseph H ^a   Li, Yiping ^b   Anderson, Paul A ^b  

^a CHILDREN S HOSPITAL OF ALABAMA   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Allograft; Bone morphogenetic protein 2; Bone morphogenetic protein 7; Complications; Pediatric; Spine fusion

Indexed keywords

RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN;

ACID ASPIRATION; ACUTE HEART INFARCTION; ADOLESCENT; ARTICLE; BRAIN DAMAGE; BRAIN HYPOXIA; CARDIOGENIC SHOCK; CHILD; COCHRANE LIBRARY; FEMALE; HUMAN; LACERATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDLINE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REOPERATION; SEROMA; SEX DIFFERENCE; SPINE FUSION; SURGICAL WOUND; SYSTEMATIC REVIEW; THROMBOPHLEBITIS; VEIN EMBOLISM; WOUND DEHISCENCE; FACTUAL DATABASE; INTERNATIONAL CLASSIFICATION OF DISEASES; YOUNG ADULT;

ADOLESCENT; BONE MORPHOGENETIC PROTEINS; CHILD; DATABASES, FACTUAL; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; POSTOPERATIVE PERIOD; REOPERATION; SPINAL FUSION; YOUNG ADULT;

EID: 84922480478     PISSN: 19330707     EISSN: 19330715     Source Type: Journal    
DOI: 10.3171/2014.8.PEDS13665     Document Type: Article

References (19)

1. Abd-El-Barr MM, Cox JB, Antonucci MU, Bennett J, Murad GJA, Pincus DW: Recombinant human bone morphogenetic protein-2 as an adjunct for spine fusion in a pediatric population. Pediatr Neurosurg 47:266-271, 2011
2. Cahill KS, Chi JH, Day A, Claus EB: Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 302: 58-66, 2009
3. Carragee EJ, Chu G, Rohatgi R, Hurwitz EL, Weiner BK, Yoon ST, et al: Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis. J Bone Joint Surg Am 95:1537-1545, 2013
4. Carragee EJ, Hurwitz EL, Weiner BK: A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11:471-491, 2011
5. Cooper GS, Kou TD: Risk of cancer after lumbar fusion surgery with recombinant human bone morphogenic protein-2 (rh-BMP-2). Spine (Phila Pa 1976) 38:1862-1868, 2013
6. Dodwell E, Snyder B, Wright J: Off-label use of bone morphogenetic proteins in pediatric spinal arthrodesis. JAMA 308:1429-1432, 2012
7. Fahim DK, Whitehead WE, Curry DJ, Dauser RC, Luerssen TG, Jea A: Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine: safety profile and efficacy in the early postoperative period. Neurosurgery 67:1195-1204, 2010
8. Glassman SD, Howard J, Dimar J, Sweet A, Wilson G, Carreon L: Complications with recombinant human bone morphogenic protein-2 in posterolateral spine fusion: a consecutive series of 1037 cases. Spine (Phila Pa 1976) 36:1849-1854, 2011
9. Gressot LV, Patel AJ, Hwang SW, Fulkerson DH, Jea A: Rh-BMP-2 for L5-S1 arthrodesis in long fusions to the pelvis for neuromuscular spinal deformity in the pediatric age group: analysis of 11 patients. Childs Nerv Syst 30:249-255, 2014
10. Jain A, Kebaish KM, Sponseller PD: Factors associated with use of bone morphogenetic protein during pediatric spinal fusion surgery: an analysis of 4817 patients. J Bone Joint Surg Am 95:1265-1270, 2013
11. Lad SP, Bagley JH, Karikari IO, Babu R, Ugiliweneza B, Kong M, et al: Cancer after spinal fusion: the role of bone morphogenetic protein. Neurosurgery 73:440-449, 2013
12. Lindley TE, Dahdaleh NS, Menezes AH, Abode-Iyamah KO: Complications associated with recombinant human bone morphogenetic protein use in pediatric craniocervical arthrodesis. Clinical article. J Neurosurg Pediatr 7:468-474, 2011
13. Oetgen ME, Richards BS: Complications associated with the use of bone morphogenetic protein in pediatric patients. J Pediatr Orthop 30:192-198, 2010
14. Ong KL, Villarraga ML, Lau E, Carreon LY, Kurtz SM, Glassman SD: Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila Pa 1976) 35:1794-1800, 2010
15. Thawani JP, Wang AC, Than KD, Lin CY, La Marca F, Park P: Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery 66:233-246, 2010
16. US Food and Drug Administration: FDA Public Health Notification: Life-Threatening Complications Associated With Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion. Silver Spring, MD: FDA, 2008 (http://www.fda.gov/medicaldevices/safety/alertsandnotices/publichealthnotifications/ucm062000.htm) [Accessed August 19, 2014]
17. Wang MC, Chan L, Maiman DJ, Kreuter W, Deyo RA: Complications and mortality associated with cervical spine surgery for degenerative disease in the United States. Spine (Phila Pa 1976) 32:342-347, 2007
18. Weingart SN, Iezzoni LI, Davis RB, Palmer RH, Cahalane M, Hamel MB, et al: Use of administrative data to find substandard care: validation of the complications screening program. Med Care 38:796-806, 2000
19. Williams BJ, Smith JS, Fu KMG, Hamilton DK, Polly DW Jr, Ames CP, et al: Does bone morphogenetic protein increase the incidence of perioperative complications in spinal fusion? A comparison of 55,862 cases of spinal fusion with and without bone morphogenetic protein. Spine (Phila Pa 1976) 36:1685-1691, 2011